Highest-materiality recent filing
Filed an 8-K on August 5, 2026, to furnish an updated corporate presentation as Exhibit 99.1.
Context Therapeutics receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Context on July 29, 2026 of non-compliance with Minimum Bid Price Rule (bid below $1.00 for 30 consecutive business days).
Context Therapeutics stockholders approve increase in authorized common shares to 300M
Authorized common shares increased from 200M to 300M via Certificate of Amendment filed June 24, 2026.
Context Therapeutics reports 29% ORR for CTIM-76 in Phase 1 PROC trial; FDA Fast Track granted
29% confirmed overall response rate per RECIST v1.1 in heavily pretreated PROC patients (median 7 prior lines).
Paid $4.5M upfront and $2M due by Aug 1, 2026 to eliminate all future milestone/royalty obligations.
Context Therapeutics resolves stockholder class action; $850K mootness fee paid by third party
Delaware court invalidated classified board and for-cause removal provisions from charter.
Context Therapeutics receives FDA Fast Track for CTIM-76 in platinum-resistant ovarian cancer
FDA granted Fast Track Designation for CTIM-76 (CLDN6 x CD3 bispecific antibody) in PROC after all standard therapies.
Presentation updated March 23, 2026 for investor and analyst meetings.
Context Therapeutics removes classified board and for-cause removal after court-approved settlement
Court approved stipulation invalidating 3-year director terms and for-cause removal provisions from charter.
Context Therapeutics settles governance lawsuit; annual director elections June 24, 2026
Stipulated consent judgment filed Feb 24 invalidates three-year director terms and for-cause removal from charter.
Context Therapeutics files updated corporate presentation; no material new information disclosed
Filing updates corporate presentation for investor meetings; presentation content not included in this 8-K.
Context Therapeutics Q3 net loss $9.7M; early clinical data for CTIM-76 and CT-95
Q3 net loss $9.7M, down from $17.5M YoY; cash $76.9M sufficient into 2027.
Context Therapeutics amends ATM agreement to increase offering capacity to up to $75M
Prior ATM: sold 14.7M shares for ~$15M through Dec 2, 2024 to Oct 24, 2025.
Context Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq letter on Oct 17, 2025 confirming compliance regained after 10 consecutive business days with closing bid price at or above $1.00.
Context Therapeutics receives Nasdaq extension until Feb 23, 2026 for bid price compliance
Received Nasdaq extension letter on Aug 28, 2025; new compliance deadline Feb 23, 2026.
66,716,026 shares (74.37% of outstanding) present at June 12, 2025 annual meeting.
Context Therapeutics updates corporate presentation for June 2025
Company issued an updated corporate presentation dated June 2025.
Context Therapeutics doses first patient in Phase 1 trial of CT-95 bispecific antibody
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody targeting MSLN-expressing cancers.
Context Therapeutics receives Nasdaq minimum bid price deficiency notice
Received Nasdaq deficiency notice on Feb 27, 2025 for failing $1.00 minimum bid price for 30 consecutive business days.
Context Therapeutics doses first patient in Phase 1 trial of CTIM-76 for CLDN6-positive cancers
First patient dosed in Phase 1 open-label trial of CTIM-76 (CLDN6 x CD3 bispecific antibody).
Context Therapeutics appoints Andy Pasternak as Chairman; Richard Berman resigns from Board
Richard Berman resigned from Board effective Jan 12, 2025; not due to any disagreement with the Company.
Context Therapeutics sells 14.7M shares for ~$15M to MPM BioImpact
Sold 14,705,882 shares at ~$1.02/share for aggregate gross proceeds of ~$15M.
Context Therapeutics enters $75M at-the-market equity offering with Leerink Partners
ATM facility allows sale of up to $75M of common stock from time to time.
Context Therapeutics licenses Nectin-4 x CD3 TCE bispecific from BioAtla for up to $133.5M
$15M upfront/near-term plus up to $118.5M milestones and tiered royalties on net sales.
Context Therapeutics stockholders approve doubling authorized shares to 200M
Stockholders voted 42,389,461 for, 790,853 against, 71,655 abstain to increase authorized common shares to 200,000,000.
Board size increased from 5 to 7; Dr. Smith (former CMO of Jazz Pharmaceuticals) and Dr. Walker (former CMO of Harpoon Therapeutics) join.
Context Therapeutics acquires CT-95 (mesothelin x CD3 T cell engager) for $3.75M
Acquired CT-95 from Link (assignment for benefit of creditors) for $3.75M upfront payment.
Context Therapeutics Stockholders Ratify Auditor and Elect Directors at Annual Meeting
Ratified CohnReznick LLP as auditor for 2024 with 8,364,879 votes for, 117,835 against.
Context Therapeutics raises ~$100M via private placement; FDA clears IND for CTIM-76
Private placement raises ~$100M gross via 64.5M shares/pre-funded warrants at $1.55/share.
Context Therapeutics submits IND for CTIM-76 Phase 1 trial in CLDN6-positive cancers
IND filed March 28, 2024 with FDA for CTIM-76, a CLDN6 x CD3 bispecific antibody.
Context Therapeutics amends bylaws to reduce quorum to one-third, update proxy rules
Quorum reduced to one-third of outstanding shares entitled to vote, effective immediately.
Discovered third-party patents expiring Jan 2034 may cover CTIM-76; company believes it has defenses but may not prevail.
CTIM-76 induced dose-proportional tumor regressions and was well tolerated in xenograft models.
Context Therapeutics updates corporate presentation for investor meetings
On August 7, 2023, Context Therapeutics updated its corporate presentation for use in investor meetings.
Context Therapeutics regains Nasdaq minimum bid price compliance
Non-compliance with Minimum Bid Price Rule first disclosed on Jan 24, 2023; initial cure period ran to July 24, 2023.
Context Therapeutics 2023 annual meeting: auditor ratified, reverse stock split not approved
Ratification of CohnReznick LLP as independent auditor for FY2023 approved with 9,827,096 for, 232,432 against, 109,961 abstentions.
Context Therapeutics discontinues ONA-XR, prioritizes CTIM-76; 2022 net loss $14.8M
Discontinued ONA-XR due to elevated LFTs in 3 patients and competitive landscape; exploring strategic options.
Context Therapeutics reports positive Phase 2 OATH data for ONA-XR in endometrial cancer
Two confirmed partial responses among first 12 patients (9 evaluable) in Phase 2 trial of ONA-XR plus anastrozole for HR+ metastatic endometrial cancer.
Context Therapeutics receives Nasdaq notice for non-compliance with minimum bid price rule
Received Nasdaq deficiency notice on Jan 24, 2023, for bid price below $1.00 for 30 consecutive business days.
CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody candidate; IND filing expected Q1 2024.
4-month progression-free survival (PFS) rate of 44% in ER+, HER2- metastatic breast cancer patients in SMILE trial.
Context Therapeutics nominates CTIM-76 as lead CLDN6 bispecific; IND expected Q1 2024
CTIM-76 is a CLDN6 x CD3 bispecific antibody with silenced Fc to reduce aberrant T-cell activation.
Context Therapeutics updates corporate deck; no new material financial or clinical details.
Corporate presentation updated as of November 2022 for investor meetings.
Context Therapeutics extends cash runway to Q1 2024, prioritizes key pipeline programs
Cash runway extended to Q1 2024; deferring noncritical R&D and reducing overhead.
Phase 1b/2 ELONA trial evaluating ONA-XR plus elacestrant expected to start Q4 2022.
Context Therapeutics shareholders ratify CohnReznick as auditor for FY 2022
Annual meeting held June 2, 2022; quorum of 9,161,941 shares (57.38%) present.
Context Therapeutics reports FY2021 net loss of $10.5M; cash $49.7M into 2024
Cash, equivalents and restricted cash $49.7M at Dec 31, 2021 (vs $0.3M in 2020); expected to fund operations into 2024.
Context Therapeutics updates corporate presentation, no new figures disclosed
Filed an updated corporate presentation dated January 2022 under Item 8.01.
Context Therapeutics announces leadership changes: Rencher retires, Beck and Fletcher appointed
Bill Rencher, Ph.D., retired as Head of CMC effective Jan 1, 2022; transitions to advisory role at $8,000/month through Apr 2022.
Context Therapeutics closes $31.25M private placement of 5M shares and warrants
Gross proceeds of ~$31.25M from sale of 5M shares of common stock and 5M warrants at $6.25 per unit.
On January 10, 2025, Richard Berman gave notice of his resignation from the Board of Directors (the “Board”) of Context Therapeutics Inc. (the "Company"), effective as of January 12, 2025.
the Board appointed Andy Pasternak as a member and Chairperson of the Board, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.
On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.
On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.
As of January 1, 2022, Bill Rencher, Ph.D., retired as Head of Chemistry Manufacturing Controls of Context Therapeutics Inc. (the “Company”), and transitioned into an advisory role with the Company.
On November 1, 2021, Context Therapeutics Inc. (the “Company”) appointed Jennifer Minai-Azary as the Company’s Chief Financial Officer.
Max materiality 0.85 · Median 0.60 · Most common event other_material